Advancing Non-Systemic Medicines for Inflammatory Skin Diseases

Turn Therapeutics develops first-in-class topical therapies that act within the skin to prevent unnecessary immune activation without systemic exposure or injections.

Turn Therapeutics is a clinical-stage biotechnology company advancing first-in-class therapies designed to act where disease occurs, not where it does not.

Our approach is grounded in a simple principle: effective medicine should deliver therapeutic impact locally, without unnecessary systemic exposure.

We are building a new category of precision therapeutics designed to deliver meaningful, sustained efficacy through non-systemic local delivery, beginning in dermatologic inflammation across the full spectrum of disease severity.

Breakthrough Science, Precisely Where It Is Needed

A Promising Therapeutic Direction for Inflammatory Skin Diseases

Currently approved treatments for moderate-to-severe eczema largely rely on systemic biologics and oral therapies that affect immune function throughout the body, not just at the site of inflammation.

These therapies are associated with safety and tolerability profiles that can affect long-term adherence.

The Result

Burden of

systemic biologics

Growing demand

for alternatives

Localized

cytokine modulation

GX-03: A First-in-Class Topical Therapy That Designed to Stop Inflammation at Its Source

GX-03 alters the cutaneous microenvironment, conditioning it to produce less IL-36α, IL-36γ, IL-31, and IL-4 — the central drivers of itch and inflammation in eczema —delivering strong anti-inflammatory effects directly to the site.